Faber Logo Skip to main content
Woman putting coin into piggy bank

Client Groups

Venture Capital & Private Equity Investors

Private capital drives the translation of new learnings in basic science to the development of products that meet medical needs. Notwithstanding the proliferation of “industry standard” venture financing documents, crafting the financial and governance terms of a financing to align the interests of scientific founders and investors remains an art.


Faber has deep experience counseling a significant number of the most prominent U.S.-based life science venture capital and private equity firms. Our experience is broad, and we routinely guide investor clients on seed and later-stage financing transactions, new company incubation activities, and strategic transactions and exits impacting portfolio companies.

In each case, the Faber deal team brings to bear its deep experience serving as outside general or transactional counsel to its discovery and clinical stage therapeutic and other life science companies.

We have strong relationships with the investor groups that focus on the biotech and life science verticals and have advised many of them on their own transactions.

A deeper understanding

We understand our venture capital and private equity clients’ priorities and needs – the value drivers and vulnerabilities that inform valuation and execution risk - because we so deeply understand the priorities and needs of their prospective portfolio companies.
This knowledge positions the Faber team to efficiently and thoughtfully structure investments, advise on key governance and fiduciary considerations, and, perhaps most critically, diligence the truly material risks for the archetypal prospective portfolio company: its foundational in-licenses from academia, its partnering and collaboration relationships, and its clinical contracting and supply chain agreements.
Kurt Machemer Speaking

We know the pressure points because our team lives and breathes these deals and issues on a daily basis. The net result is sophisticated risk assessment and execution for our investor clients and, we think, portfolio companies left with a greater percentage of their financing proceeds to direct towards their important research and development objectives.

This site uses cookies. Some provide anonymous analysis of how our website is used and some are essential to make the website work. Other cookies enable personalized services or social media features to be used. By using our website, you agree to the use of cookies. To find out more, please see our Privacy Policy. You can disable cookies at any time by changing your browser settings.